Cytomegalovirus Infection Risk Factors in Allogeneic Hematopoietic Stem Cell Transplantation Can Defibrotide Be a Risk Factor?

Basit Öğe Kaydı
dc.contributor.authorYilmaz, Zeynep Burcin
dc.contributor.authorMemisoglu, Funda
dc.contributor.authorHidayet, Emine
dc.contributor.authorKuku, Irfan
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorKaya, Emin
dc.contributor.authorBerber, Ilhami
dc.date.accessioned2026-04-04T13:34:46Z
dc.date.available2026-04-04T13:34:46Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractIntroduction and Purpose. Cytomegalovirus (CMV) infection is a prevalent complication, affecting 30% to 50% of patients following Allogeneic Hematopoietic Stem Cell Transplantation (allo-AHCT). This study aims to investigate the risk factors contributing to CMV infection development. Materials and Methods. A retrospective analysis was performed on 196 patients with hematological malignancies who underwent allo-HSCT in the Stem Cell Transplantation Unit of Inonu University Faculty of Medicine over a 5-year period. Propensity scores were calculated by matching 1:1 for gender and age variables in individuals with CMV infection and in the control group. Results. Of the 196 patients included in the study, 75 (38.3 %) were female and 121 (61.7 %) were male. According to univariate analysis, CMV infection was seen more frequently in ALL patients than in AML patients (p = .012), while the conditioning regimen (p = 1) did not affect the outcome in terms of risk. Blood cyclosporine levels measured simultaneously with CMV positivity were significant in terms of risk (p = .006). A significant correlation was found between GvHD and CMV infection (p < .001). According to multivariate analysis, receiving defibrotide for VOD prophylaxis posed a risk for CMV positivity. Conclusion. In our study, only defibrotide prophylaxis was noted as a risk factor in multivariate analysis. While there are ongoing studies for the use of defibrotide in GVHD prophylaxis, more studies are needed to say that it is a definite risk factor for CMV. We believe that focusing on prophylactic treatments used during the transplantation process will be guiding in determining risk factors.
dc.identifier.doi10.1016/j.transproceed.2025.05.018
dc.identifier.endpage1142
dc.identifier.issn0041-1345
dc.identifier.issn1873-2623
dc.identifier.issue6
dc.identifier.orcid0000-0002-3285-417X
dc.identifier.orcid0000-0003-3121-7387
dc.identifier.orcid0000-0002-6950-6013
dc.identifier.orcid0000-0001-8605-8497
dc.identifier.orcid0000-0003-3312-8476
dc.identifier.orcid0000-0001-6126-0816
dc.identifier.pmid40581568
dc.identifier.scopus2-s2.0-105009323362
dc.identifier.scopusqualityQ3
dc.identifier.startpage1133
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2025.05.018
dc.identifier.urihttps://hdl.handle.net/11616/109393
dc.identifier.volume57
dc.identifier.wosWOS:001542004100021
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofTransplantation Proceedings
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectCmv Infection
dc.subjectReactivation
dc.subjectGuidelines
dc.titleCytomegalovirus Infection Risk Factors in Allogeneic Hematopoietic Stem Cell Transplantation Can Defibrotide Be a Risk Factor?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu